AU2018325899B2 - Method for producing influenza HA split vaccine - Google Patents

Method for producing influenza HA split vaccine Download PDF

Info

Publication number
AU2018325899B2
AU2018325899B2 AU2018325899A AU2018325899A AU2018325899B2 AU 2018325899 B2 AU2018325899 B2 AU 2018325899B2 AU 2018325899 A AU2018325899 A AU 2018325899A AU 2018325899 A AU2018325899 A AU 2018325899A AU 2018325899 B2 AU2018325899 B2 AU 2018325899B2
Authority
AU
Australia
Prior art keywords
influenza
split vaccine
vaccine
lah
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018325899A
Other languages
English (en)
Other versions
AU2018325899A1 (en
Inventor
Yu Adachi
Manabu ATO
Yoshimasa Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Infectious Diseases
Original Assignee
National Institute of Infectious Diseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute of Infectious Diseases filed Critical National Institute of Infectious Diseases
Priority claimed from PCT/JP2018/032537 external-priority patent/WO2019045090A1/ja
Publication of AU2018325899A1 publication Critical patent/AU2018325899A1/en
Assigned to JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES reassignment JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES Request for Assignment Assignors: JAPAN HEALTH SCIENCES FOUNDATION
Application granted granted Critical
Publication of AU2018325899B2 publication Critical patent/AU2018325899B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018325899A 2017-09-04 2018-09-03 Method for producing influenza HA split vaccine Active AU2018325899B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2017169230 2017-09-04
JP2017-169230 2017-09-04
JP2018137952A JP7403733B2 (ja) 2017-09-04 2018-07-23 インフルエンザｈａスプリットワクチンの製造方法
JP2018-137952 2018-07-23
PCT/JP2018/032537 WO2019045090A1 (ja) 2017-09-04 2018-09-03 インフルエンザｈａスプリットワクチンの製造方法

Publications (2)

Publication Number Publication Date
AU2018325899A1 AU2018325899A1 (en) 2020-04-09
AU2018325899B2 true AU2018325899B2 (en) 2023-04-20

Family

ID=65815411

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018325899A Active AU2018325899B2 (en) 2017-09-04 2018-09-03 Method for producing influenza HA split vaccine

Country Status (10)

Country Link
US (1) US11732031B2 (enExample)
EP (1) EP3679948A4 (enExample)
JP (1) JP7403733B2 (enExample)
KR (1) KR102733152B1 (enExample)
CN (1) CN111372605B (enExample)
AU (1) AU2018325899B2 (enExample)
CA (1) CA3074581A1 (enExample)
EA (1) EA202090587A1 (enExample)
PH (1) PH12020500414A1 (enExample)
SG (1) SG11202001937TA (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
TW202011986A (zh) 2018-07-23 2020-04-01 公益財團法人日本健康科學振興財團 包含流感疫苗之組合物
PH12021552094A1 (en) 2019-03-04 2022-05-30 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases Method for preparing influenza ha split vaccine
CN114929270A (zh) * 2019-11-07 2022-08-19 塞其里斯英国有限公司 用于生产具有减小的颗粒大小的病毒疫苗的组合物和方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278083B2 (en) 2004-03-22 2012-10-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inactivated influenza virus compositions
JPWO2008114819A1 (ja) 2007-03-20 2010-07-08 大日本住友製薬株式会社 新規アデニン化合物
KR20110049802A (ko) 2008-07-25 2011-05-12 인스티튜트 포 리서치 인 바이오메드슨 중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도
WO2010047509A2 (ko) 2008-10-24 2010-04-29 아주대학교 산학협력단 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물
CN101524538A (zh) * 2009-03-26 2009-09-09 成都康华生物制品有限公司 一种流感-大流行流感二价联合疫苗及其制备方法
JP5795340B2 (ja) 2010-03-08 2015-10-14 セルトリオン インクＣｅｌｌｔｒｉｏｎ，Ｉｎｃ． インフルエンザａ型ウイルスに対して中和活性を有するヒトｂ細胞由来のヒトモノクローナル抗体
JP2013526849A (ja) 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
US8940517B2 (en) 2011-04-21 2015-01-27 Baxter International Inc. Methods for isolating and quantifying antigen from vaccines
US20150098966A1 (en) * 2012-05-16 2015-04-09 Kj Biosciences Llc Influenza vaccines
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
SG11201701279VA (en) * 2014-08-18 2017-03-30 Sanofi Pasteur Inc Alkylated influenza vaccines
KR102713707B1 (ko) 2014-12-31 2024-10-04 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 신규 다가 나노입자 기반 백신
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
TW202011986A (zh) 2018-07-23 2020-04-01 公益財團法人日本健康科學振興財團 包含流感疫苗之組合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHENG DAN ET AL: "Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses", VACCINE, vol. 34, no. 51, 2016, pages 6464 - 6471 *

Also Published As

Publication number Publication date
CA3074581A1 (en) 2019-03-07
EP3679948A1 (en) 2020-07-15
EA202090587A1 (ru) 2020-08-24
CN111372605A (zh) 2020-07-03
CN111372605B (zh) 2024-12-17
AU2018325899A1 (en) 2020-04-09
KR102733152B1 (ko) 2024-11-21
JP2019043937A (ja) 2019-03-22
JP7403733B2 (ja) 2023-12-25
EP3679948A4 (en) 2021-04-28
PH12020500414A1 (en) 2021-03-08
US20190345231A1 (en) 2019-11-14
SG11202001937TA (en) 2020-04-29
KR20200047629A (ko) 2020-05-07
US11732031B2 (en) 2023-08-22

Similar Documents

Publication Publication Date Title
AU570929B2 (en) Broad spectrum influenza antisera
AU2018325899B2 (en) Method for producing influenza HA split vaccine
AU2011344126B2 (en) Vaccine antigens that direct immunity to conserved epitopes
US4625015A (en) Broad spectrum influenza antisera
CN101227919B (zh) 基于肽的流感疫苗制剂
Du et al. Flu universal vaccines: new tricks on an old virus
US12491240B2 (en) Method for producing influenza HA split vaccine
JP2023052092A (ja) 免疫原性組成物
JPH02503916A (ja) Ｈｉｖエンベロープ蛋白質に関連する合成ペプチド
US20230406910A1 (en) Method for producing influenza ha split vaccine
WO2011024748A1 (ja) インフルエンザm2由来の改変ペプチドワクチン
WO2009152518A1 (en) Novel peptide adjuvant for influenza vaccination
HK40032891A (en) Method for producing influenza ha split vaccine
TWI857017B (zh) 流感ha裂解疫苗之製造方法
EA045852B1 (ru) Способ получения сплит-вакцины с ha гриппа
EA045912B1 (ru) Способ приготовления сплит-вакцины на основе гемагглютинина гриппа
HK40068192A (en) Method for preparing influenza ha split vaccine
WO2015093996A1 (en) Antigen, influenza vaccine, system for vaccine manufacturing, method of antigen production, and use of antigen to produce an influenza vaccine
US20120156242A1 (en) An Antigenic Peptide Derived From Influenza Virus And A Method For Selecting Anti-Influenza Virus Antibody
Jiang et al. Antibody Cross-Reactivity to Hemagglutinin Protein Antigens Demonstrates Feasibility for Development of a “Universal” Influenza A Synthetic Peptide Vaccine

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES

Free format text: FORMER APPLICANT(S): JAPAN HEALTH SCIENCES FOUNDATION

FGA Letters patent sealed or granted (standard patent)